Association of medication adherence with clinical outcomes and quality of life in type 2 diabetes mellitus patients: a cross-sectional study

Selly Septi Fandinata; Deddy Aryanda Putra; Eziah Ika Lubada; Silfiana Nisa Permata Sari; Chinthia Devientasari; Iin Ernawati; Mercyska Suryandari; Dini Berliana

doi:10.34011/jmp2k.v36i1.2218

Authors

Selly Septi Fandinata Universitas STRADA Indonesia, Indonesia
Deddy Aryanda Putra Universitas Airlangga, Surabaya, Indonesia, Indonesia
Eziah Ika Lubada Akademi Farmasi Surabaya, Surabaya, Indonesia, Indonesia
Silfiana Nisa Permata Sari Akademi Farmasi Surabaya, Surabaya, Indonesia, Indonesia
Chinthia Devientasari Universitas STRADA Indonesia, Indonesia
Iin Ernawati Akademi Farmasi Surabaya, Surabaya, Indonesia, Indonesia
Mercyska Suryandari Akademi Farmasi Surabaya, Surabaya, Indonesia, Indonesia
Dini Berliana Universitas STRADA Indonesia, Indonesia

DOI:

https://doi.org/10.34011/jmp2k.v36i1.2218

Keywords:

digital health interventions, health-related qualiyt of life, medication adherence, type 2 diabetes mellitus

Abstract

Background: Type 2 diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. Patient adherence to medication is a critical factor in effective management, as it can reduce morbidity and mortality while improving health-related quality of life (HRQoL). Digital interventions, such as smartphone-based medication reminder applications, represent a promising strategy to enhance adherence.

Objective: This study aimed to examine the relationship between medication adherence and clinical outcomes, specifically fasting blood glucose levels and HRQoL, among patients with type 2 diabetes in primary health care settings.

Methods: A cross-sectional pre–post test design was employed involving 96 respondents, divided equally into control and intervention groups, selected through convenience sampling. Primary data were collected using the MARS-10 adherence questionnaire and the DQOL Brief Clinical Inventory, while secondary data were obtained from pre– and post–fasting blood glucose measurements.

Results: Results showed no significant relationship between medication adherence and fasting blood glucose levels (p > 0.05), nor between adherence and HRQoL (p > 0.05), even with the implementation of the Drug Reminder App intervention.

Conclusion: These findings highlight the need for additional interventions or further innovations in digital adherence support to improve clinical and quality-of-life outcomes in type 2 diabetes management.

References

[1] L. Vinet and A. Zhedanov, “A ‘missing’ family of classical orthogonal polynomials,” J. Phys. A Math. Theor., vol. 44, no. 8, p. 085201, Feb. 2011, doi: 10.1088/1751-8113/44/8/085201.

[2] S. Webber, “Five questions on the IDF Diabetes Atlas,” in IDF Diabetes Atlas, 2021, pp. 1–141. doi: 10.1016/j.diabres.2013.10.013.

[3] WHO, “Diabetes Programme,” World Heal. Organ., 2018. link : https://www.who.int/teams/noncommunicable-diseases/ncds-management/diabetes-programme

[4] S. Soelistijo et al., Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe2 Di Indonesia 2015. 2015.

[5] American Diabetes Association, “2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019,” Diabetes Care, vol. 42, no. Supplement 1, pp. S13–S28, Jan. 2019, doi: 10.2337/dc19-S002.

[6] S. Cho et al., “Association of cardiovascular health with the risk of dementia in older adults,” Sci. Rep., vol. 12, no. 1, p. 15673, Sep. 2022, doi: 10.1038/s41598-022-20072-3.

[7] M. Nafea, A. Kubais, N. A. Galil, M. Hassan, and M. H. Shamsain, “Association Between Adherence To Diabetes Medication and Glycemic Control,” Int. J. Res. Dev. Pharm. Life Sci., vol. 5, no. 1, pp. 1915–1920, 2015, [Online]. Available: https://www.ijrdpl.com/index.php/ijrdpl/article/view/201

[8] A. Majeed et al., “The Impact of Treatment Adherence on Quality of Life Among Type 2 Diabetes Mellitus Patients – Findings from a Cross-Sectional Study,” Patient Prefer. Adherence, vol. Volume 15, pp. 475–481, Feb. 2021, doi: 10.2147/PPA.S295012.

[9] D. Care and S. S. Suppl, “6. Glycemic Targets: Standards of Medical Care in Diabetes—2021,” Diabetes Care, vol. 44, no. Supplement_1, pp. S73–S84, Jan. 2021, doi: 10.2337/dc21-S006.

[10] Selly Septi Fandinata, Eziah Ika Lubada, Ninik Mas Ulfa, and Rizky Darmawan, “Intervention Digital Medication Reminder App to Improve Hypertension Patient’s Self-Management Medication Adherence,” Str. J. Ilm. Kesehat., vol. 11, no. 2, pp. 117–125, Nov. 2022, doi: 10.30994/sjik.v11i2.926.

[11] S. S. Fandinata and I. Ernawati, “The Effect of Self-reminder Card to the Level of Adherence of Hypertension Patients in Community Health Center in Surabaya,” Open Access Maced. J. Med. Sci., vol. 8, no. E, pp. 647–652, Oct. 2020, doi: 10.3889/oamjms.2020.5389.

[12] R. Hasina, Probosuesno, and C. Wiedyaningsih, “Hubungan Tingkat Kepatuhan, Kepuasan Terapi dengan Kualitas Hidup Pasien Usia Lanjut Diabetes Melitus Tipe 2,” J. Manaj. dan Pelayanan Farm., vol. 4, no. 4, p. 338429, 2014, [Online]. Available: https://jurnal.ugm.ac.id/jmpf/article/view/29466/17609

[13] R. Mishra et al., “Medication adherence and quality of life among type-2 diabetes mellitus patients in India,” World J. Diabetes, vol. 12, no. 10, pp. 1740–1749, Oct. 2021, doi: 10.4239/wjd.v12.i10.1740.

[14] A. Hidayat, “Menghitung Besar Sampel Penelitian,” Metodologi. 2012.

[15] H. Permana, M. V. Liem, and N. N. M. Soetedjo, “Validation of the Indonesian Version of the Asian Diabetes Quality of Life Questionnaire,” Acta Med. Indones., vol. 53, no. 2, pp. 143–148, 2021.

[16] M. I. N. A. Wibowo, F. M. Fitri, N. M. Yasin, S. A. Kristina, and Y. S. Prabandari, “Kepatuhan Minum Obat pada Pasien Diabetes Melitus Tipe 2 di Beberapa Puskesmas Kabupaten Banyumas,” J. Kefarmasian Indones., vol. 11, no. 2, pp. 98–108, 2021.

[17] H. B. Bosworth, “Defining Medication Nonadherence,” in Enhancing Medication Adherence, Tarporley: Springer Healthcare Ltd., 2012, pp. 3–7. doi: 10.1007/978-1-908517-66-1_1.

[18] Perkumpulan Endokrinologi Indonesia, Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia. PB Perkeni, 2021.

[19] A. M. Alqarni, T. Alrahbeni, A. Al Qarni, and H. M. Al Qarni, “Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia – a cross-sectional survey,” Patient Prefer. Adherence, vol. Volume 13, pp. 63–71, Dec. 2018, doi: 10.2147/PPA.S176355.

[20] S. S. Fandinata and R. Darmawan, “Pengaruh Kepatuhan Minum Obat Oral Anti Diabetik Terhadap Kadar Gula Darah Pada Pasien Diabetes Mellitus Tipe II,” J. Bid. Ilmu Kesehat., vol. 10, no. 1, pp. 23–31, 2020.

[21] A. M. Paschal, S. R. Hawley, T. S. Romain, and E. Ablah, “Measures of adherence to epilepsy treatment: Review of present practices and recommendations for future directions,” Epilepsia, vol. 49, no. 7, pp. 1115–1122, Jul. 2008, doi: 10.1111/j.1528-1167.2008.01645.x.

[22] I. Ernawati, W. R. Islamiyah, and S. -, “How to Improve Clinical Outcome of Epileptic Seizure Control Based on Medication Adherence? A Literature Review,” Open Access Maced. J. Med. Sci., vol. 6, no. 6, pp. 1174–1179, Jun. 2018, doi: 10.3889/oamjms.2018.235.

[23] S. Hamedi-Shahraki et al., “Health-related quality of life and medication adherence in elderly patients with epilepsy,” Neurol. Neurochir. Pol., vol. 53, no. 2, pp. 123–130, Apr. 2019, doi: 10.5603/PJNNS.a2019.0008.

[24] F. Militia, S. Handayani, and B. Setiaji, “Kejadian Diabetes Mellitus Tipe II pada Lanjut Usia di Indonesia (Analisis Riskesdas 2018 ),” J. Kedokt. dan Kesehat., vol. 17, no. 1, pp. 9–20, 2021.

[25] N. N. Fajriyah, W. A. Ningrum, A. Muthoharoh, and T. Listiana, “Hubungan Karakteristik dengan Tingkat Kepatuhan Penggunaan Obat Pada Diabetisi Tipe 2 Prolanis Di Wilayah Kerja Puskesmas Wonopringgo Kabupaten Pekalongan. Gombong : Urecol.,” Univ. Res. Colloq., vol. 41, no. 9, pp. 2045–2047, 2019.

[26] M. Rahmawati and N. Mutmainah, “Hubungan Antara Kepatuhan Penggunaan Obat dan Keberhasilan Terapi Pada Pasien Hipertensi Di Rumah Sakit Daerah Surakarta Tahun 2010,” Pharmacon, vol. 11, no. 2, pp. 51–56, 2010.

[27] Y. Asy’ari et al., “Faktor-Faktor Yang Berhubungan Dengan Keikutsertaan Jkn Di Desa Citaringgul,” J. Fisioter. dan Kesehat. Indones., vol. 2, no. 1, pp. 2807–8020, 2022.

[28] A. A. S. Al-Rasheedi, “The Role of Educational Level in Glycemic Control among Patients with Type II Diabetes Mellitus,” Int. J. Health Sci. (Qassim)., vol. 8, no. 2, pp. 177–187, Apr. 2014, doi: 10.12816/0006084.

[29] T. Anasari, “Hubungan Pendidikan Dan Pekerjaan Dengan Kepatuhan Ibu Hamil Dengan Hiv Dalam Mengkonsumsi Arv Di Rsud Prof.Dr. Margono Soekarjo Purwokerto,” in PROSIDING: Seminar Nasional dan Presentasi Hasil-Hasil Penelitian Pengabdian Masyarakat, 2018, pp. 272–283. [Online]. Available: http://ojs.akbidylpp.ac.id/index.php/Prada/article/view/401

[30] S. S. Mukrimaa et al., Metodologi penelitian keperawatan, vol. 6, no. August. 2016.

[31] S. Notoatmodjo, Promosi Kesehatan & Ilmu Perilaku. 2012.

[32] R. K. Sinuraya, D. P. Destiani, I. M. Puspitasari, and A. Diantini, “Medication Adherence among Hypertensive Patients in Primary Healthcare in Bandung City,” Indones. J. Clin. Pharm., vol. 7, no. 2, pp. 124–133, Jun. 2018, doi: 10.15416/ijcp.2018.7.2.124.

[33] S. S. Fandinata, R. Darmawan, and A. F. Surabaya, “Perbedaan Kepatuhan Minum Obat Pada Pasien Yang Baru Terdiagnosa Dan Sudah Lama Terdiagnosa Penyakit Diabetes Melitus Tipe 2,” jurnal.akfarsam.ac.id, 2020.

[34] S. S. Fandinata and R. Darmawan, “Pengaruh Kepatuhan Minum Obat Oral Anti Diabetik Terhadap Kadar Gula Darah Pada Pasien Diabetes Mellitus Tipe II,” J. Bid. Ilmu Kesehat., 2020.

[35] S. K. Saha and A. Jha, “Impact of reminder on medication adherence: a structural equation model, based on study in Sikkim, India,” Biosci. J., vol. 38, p. e38014, Feb. 2022, doi: 10.14393/BJ-v38n0a2022-59087.

[36] H. Shahbazi, F. Ghofranipour, P. Amiri, and A. Rajab, “Factors Affecting Self-Care Performance in Adolescents with Type I Diabetes According to the PEN-3 Cultural Model,” Int. J. Endocrinol. Metab., vol. In Press, no. In Press, Sep. 2018, doi: 10.5812/ijem.62582.

[37] PERKENI, Pemantauan gula darah mandiri. 2021.

[38] K. B. Rahayu, L. D. Saraswati, and H. Setyawan, “Faktor-Faktor yang Berhubungan Dengan Kadar Gula Darah Pada Penderita Diabetes Melitus Tipe 2 (Studi di Wilayah Kerja Puskesmas Kedungmundu Kota Semarang),” J. Kesehat. Masy., vol. 6, no. 2, pp. 19–28, 2018, [Online]. Available: http://ejournal3.undip.ac.id/index.php/jkm

[39] S. Septi Fandinata and I. Ernawati, “Management terapi pada penyakit degeneratif,” Mengenal, mencegah, dan mengatasi penyakit Degener. (diabetes melitus dan Hipertens., pp. 1–134, 2020, [Online]. Available: http://repository.akfarsurabaya.ac.id/393/

[40] N. Rasdianah, S. Martodiharjo, T. M. Andayani, and L. Hakim, “The Description of Medication Adherence for Patients of Diabetes Mellitus Type 2 in Public Health Center Yogyakarta,” Indones. J. Clin. Pharm., vol. 5, no. 4, pp. 249–257, 2016, doi: 10.15416/ijcp.2016.5.4.249.

[41] J. Oliva, A. Fernández-Bolaños, and Á. Hidalgo, “Health- related quality of life in diabetic people with different vascular risk,” BMC Public Health, vol. 12, no. 1, p. 812, Dec. 2012, doi: 10.1186/1471-2458-12-812.

[42] L. de F. Gusmai, T. de S. Novato, and L. de S. Nogueira, “The influence of quality of life in treatment adherence of diabetic patients: a systematic review,” Rev. da Esc. Enferm. da USP, vol. 49, no. 5, pp. 839–846, Oct. 2015, doi: 10.1590/S0080-623420150000500019.

[43] Y. V. Martínez, C. A. Prado-Aguilar, R. A. Rascón-Pacheco, and J. J. Valdivia-Martínez, “Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study,” BMC Health Serv. Res., vol. 8, no. 1, p. 164, Dec. 2008, doi: 10.1186/1472-6963-8-164.

[44] A. A. Al Hayek, A. A. Robert, A. Al Saeed, A. A. Alzaid, and F. S. Al Sabaan, “Factors Associated with Health-Related Quality of Life among Saudi Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Survey,” Diabetes Metab. J., vol. 38, no. 3, p. 220, 2014, doi: 10.4093/dmj.2014.38.3.220.